血清可溶性白细胞介素2受体表达与急性淋巴细胞性白血病复发的关系

目的:探讨血清可溶性白细胞介素2受体(solubility interleukin receptor,sIL-2R)表达水平与急性淋巴细胞性白血病(acute lymphoblastic leukemia,ALL)复发的关系.方法:采用双抗体夹心酶联免疫吸附法,检测48例ALL患者初诊、复发未治疗前及第1次完全缓解后sIL-2R表达水平.结果:ALL初诊组和复发组sIL-2R表达水平显著高于正常对照组,而在ALL缓解组与正常人比较,差异没有统计学意义;初诊或复发组患者sIL-2R水平显著高于缓解组;动态观察30例患者发现,治疗有效达到完全缓解时sIL-2R水平明显下降,而病情复发时患者sIL-2R水平显著上升,sIL-2R水平上升出现在骨髓细胞形态学确诊之前一个月左右.结论:动态检测完全缓解后患者sIL-2R表达水平,有利于ALL复发早期诊断.

Relation between the expression of sIL-2R and the relapse in patients with acute lymphoblastic leukemia

Objective: To explore the relation of the serum level of sIL-2R in relapse patients with acute lymphoblastic leukemia(ALL). Methods:With ELISA, we determined the levels of sIL-2R of 48 patients with ALL after their first diagnoses,complete remission 1 and relapse. The levels of sIL-2R of 30 patients from complete remission 1 to relapse were monitored. Results: The levels of sIL-2R were higher in the relapse group and first diagnosed group than in the control. The levels of sIL-2R were higher in the relapse group and first diagnosed group than in the complete remission 1 group. However,the difference between the complete remission 1 and the control had no statistical significance. When we determined the levels of sIL-2R dynamically, we found that after complete remission ,the levels of sIL-2R decreased,however, before one month of hematological relapse, the levels of sIL-2R increased. Conclusion: Monitor of the level of sIL-2R can predict impending relapse of patients with ALL and is helpful to early diagnosis of relapse.